QurAlis Receives Clinical Trial Authorisation (CTA) in the U.K. for QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS

U.K. CTA marks third regulatory clearance for Phase 1 ANQUR clinical trial of QRL-201 in ALS QurAlis recently announced EU CTA and first patient dosed in Canada; enrollment completed in Cohort 1 portion of ANQUR ANQUR is first-ever clinical trial to evaluate a therapy that rescues…